CYP2D6 phenotypes are associated with adverse outcomes related to opioid medications

References

• DowellDHaegerichTMChouRCDC guideline for prescribing opioids for chronic pain – United States, 2016JAMA2016315151624164526977696
   PubMed Web of Science ®Google Scholar
• ThorsonDBiewenPBonteBAcute Pain Assessment and Opioid Prescribing ProtocolBloomington, MNthe Institute for Clinical Systems Improvement (ICSI)2014
   Google Scholar
• PaulozziLJMackKAHockenberryJMVital signs: variation among States in prescribing of opioid pain relievers and benzodiazepines – United States, 2012MMWR Morb Mortal Wkly Rep2014632656356824990489
   PubMed Web of Science ®Google Scholar
• FrenkSMPorterKSPaulozziLJPrescription opioid analgesic use among adults: United States, 1999–2012NCHS Data Brief201518918
   PubMedGoogle Scholar
• SteinmanMAKomaikoKDFungKZRitchieCSUse of opioids and other analgesics by older adults in the United States, 1999–2010Pain Med201516231932725352175
   PubMed Web of Science ®Google Scholar
• Abdel ShaheedCMaherCGWilliamsKADayRMcLachlanAJEfficacy, tolerability, and dose-dependent effects of opioid analgesics for low back pain: a systematic review and meta-analysisJAMA Intern Med2016176795896827213267
   PubMed Web of Science ®Google Scholar
• RileyJL3rdHastieBAIndividual differences in opioid efficacy for chronic noncancer painClin J Pain200824650952018574360
   PubMed Web of Science ®Google Scholar
• KalsoEEdwardsJEMooreRAMcQuayHJOpioids in chronic non-cancer pain: systematic review of efficacy and safetyPain2004112337238015561393
   PubMed Web of Science ®Google Scholar
• BreivikHCollettBVentafriddaVCohenRGallacherDSurvey of chronic pain in Europe: prevalence, impact on daily life, and treatmentEur J Pain200610428733316095934
   PubMed Web of Science ®Google Scholar
• ChouRClarkEHelfandMComparative efficacy and safety of long-acting oral opioids for chronic non-cancer pain: a systematic reviewJ Pain Symptom Manage20032651026104814585554
   PubMed Web of Science ®Google Scholar
• XuYJohnsonAOpioid therapy pharmacogenomics for noncancer pain: efficacy, adverse events, and costsPain Res Treat2013201394301424167729
   PubMedGoogle Scholar
• TingSSchugSThe pharmacogenomics of pain management: prospects for personalized medicineJ Pain Res20169495626929662
   PubMed Web of Science ®Google Scholar
• CrewsKRGaedigkADunnenbergerHMClinical pharmacogenetics implementation consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 updateClin Pharmacol Ther201495437638224458010
   PubMed Web of Science ®Google Scholar
• KadievEPatelVRadPRole of pharmacogenetics in variable response to drugs: focus on opioidsExpert Opin Drug Metab Toxicol200841779118370860
   PubMed Web of Science ®Google Scholar
• LotschJSkarkeCLiefholdJGeisslingerGGenetic predictors of the clinical response to opioid analgesics: clinical utility and future perspectivesClin Pharmacokinet20044314983101315530129
   PubMed Web of Science ®Google Scholar
• ZahariZIsmailRInfluence of Cytochrome P450, Family 2, Subfamily D, Polypeptide 6 (CYP2D6) polymorphisms on pain sensitivity and clinical response to weak opioid analgesicsDrug Metab Pharmacokinet2014291294323759977
   PubMed Web of Science ®Google Scholar
• CandiottiKAYangZRodriguezYThe impact of CYP2D6 genetic polymorphisms on postoperative morphine consumptionPain Med200910579980519523031
   PubMed Web of Science ®Google Scholar
• YiannakopoulouEPharmacogenomics and opioid analgesics: clinical implicationsInt J Genomics2015201536897926075211
   PubMed Web of Science ®Google Scholar
• EckhardtKLiSAmmonSSchanzleGMikusGEichelbaumMSame incidence of adverse drug events after codeine administration irrespective of the genetically determined differences in morphine formationPain1998761–227339696456
   PubMed Web of Science ®Google Scholar
• LotschJRohrbacherMSchmidtHDoehringABrockmollerJGeisslingerGCan extremely low or high morphine formation from codeine be predicted prior to therapy initiation?Pain20091441–211912419395173
   PubMed Web of Science ®Google Scholar
• SlanarODupalPMatouskovaOVondrackovaHPafkoPPerlikFTramadol efficacy in patients with postoperative pain in relation to CYP2D6 and MDR1 polymorphismsBratisl Lek Listy2012113315215522428763
   PubMed Web of Science ®Google Scholar
• StamerUMMusshoffFKobilayMMadeaBHoeftAStuberFConcentrations of tramadol and O-desmethyltramadol enantiomers in different CYP2D6 genotypesClin Pharmacol Ther2007821414717361124
   PubMed Web of Science ®Google Scholar
• PoulsenLArendt-NielsenLBrosenKSindrupSHThe hypoalgesic effect of tramadol in relation to CYP2D6Clin Pharmacol Ther19966066366448988065
   PubMed Web of Science ®Google Scholar
• StamerUMLehnenKHothkerFImpact of CYP2D6 genotype on postoperative tramadol analgesiaPain20031051–223123814499440
   PubMed Web of Science ®Google Scholar
• WangGZhangHHeFFangXEffect of the CYP2D6*10 C188T polymorphism on postoperative tramadol analgesia in a Chinese populationEur J Clin Pharmacol2006621192793116960721
   PubMed Web of Science ®Google Scholar
• OttonSVSchadelMCheungSWKaplanHLBustoUESellersEMCYP2D6 phenotype determines the metabolic conversion of hydrocodone to hydromorphoneClin Pharmacol Ther19935454634727693389
   PubMed Web of Science ®Google Scholar
• SamerCFDaaliYWagnerMGenetic polymorphisms and drug interactions modulating CYP2D6 and CYP3A activities have a major effect on oxycodone analgesic efficacy and safetyBr J Pharmacol2010160491993020590588
   PubMed Web of Science ®Google Scholar
• ZwislerSTEnggaardTPMikkelsenSBrosenKSindrupSHImpact of the CYP2D6 genotype on post-operative intravenous oxycodone analgesiaActa Anaesthesiol Scand201054223224019719813
   PubMed Web of Science ®Google Scholar
• ZwislerSTEnggaardTPNoehr-JensenLThe hypoalgesic effect of oxycodone in human experimental pain models in relation to the CYP2D6 oxidation polymorphismBasic Clin Pharmacol Toxicol2009104433534419281600
   PubMed Web of Science ®Google Scholar
• AndreassenTNEftedalIKlepstadPDo CYP2D6 genotypes reflect oxycodone requirements for cancer patients treated for cancer pain? A cross-sectional multicentre studyEur J Clin Pharmacol2012681556421735164
   PubMed Web of Science ®Google Scholar
• BielinskiSJOlsonJEPathakJPreemptive genotyping for personalized medicine: design of the right drug, right dose, right time-using genomic data to individualize treatment protocolMayo Clin Proc2014891253324388019
   PubMed Web of Science ®Google Scholar
• OlsonJERyuEJohnsonKJThe Mayo Clinic Biobank: a building block for individualized medicineMayo Clin Proc201388995296224001487
   PubMed Web of Science ®Google Scholar
• St SauverJLGrossardtBRYawnBPData resource profile: the Rochester Epidemiology Project (REP) medical records-linkage systemInt J Epidemiol20124161614162423159830
   PubMed Web of Science ®Google Scholar
• ZhongWMaradit-KremersHSt SauverJLAge and sex patterns of drug prescribing in a defined American populationMayo Clin Proc201388769770723790544
   PubMed Web of Science ®Google Scholar
• BlackJL3rdWalkerDLO’KaneDJHarmandayanMFrequency of undetected CYP2D6 hybrid genes in clinical samples: impact on phenotype predictionDrug Metab Dispos201240111111922004686
   PubMed Web of Science ®Google Scholar
• JiYSkierkaJMBlommelJHPreemptive pharmacogenomic testing for precision medicine: a comprehensive analysis of five actionable pharmacogenomic genes using next-generation DNA sequencing and a customized CYP2D6 genotyping cascadeJ Mol Diagn201618343844526947514
   PubMed Web of Science ®Google Scholar
• Ingelman-SundbergMGenetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversityPharmacogenomics J20055161315492763
   PubMed Web of Science ®Google Scholar
• KirchheinerJNickchenKBauerMPharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug responseMol Psychiatry20049544247315037866
   PubMed Web of Science ®Google Scholar
• SteimerWZopfKvon AmelunxenSAllele-specific change of concentration and functional gene dose for the prediction of steady-state serum concentrations of amitriptyline and nortriptyline in CYP2C19 and CYP2D6 extensive and intermediate metabolizersClin Chem20045091623163315205367
   PubMed Web of Science ®Google Scholar
• GaedigkASimonSDPearceREBradfordLDKennedyMJLeederJSThe CYP2D6 activity score: translating genotype information into a qualitative measure of phenotypeClin Pharmacol Ther200883223424217971818
   PubMed Web of Science ®Google Scholar
• RaimundoSToscanoCKleinKA novel intronic mutation, 2988G>A, with high predictivity for impaired function of cytochrome P450 2D6 in white subjectsClin Pharmacol Ther200476212813815289790
   PubMed Web of Science ®Google Scholar
• BapiroTEHaslerJARidderstromMMasimirembwaCMThe molecular and enzyme kinetic basis for the diminished activity of the cytochrome P450 2D6.17 (CYP2D6.17) variant. Potential implications for CYP2D6 phenotyping studies and the clinical use of CYP2D6 substrate drugs in some African populationsBiochem Pharmacol20026491387139812392820
   PubMed Web of Science ®Google Scholar
• YuAKnellerBMRettieAEHainingRLExpression, purification, biochemical characterization, and comparative function of human cytochrome P450 2D6.1, 2D6.2, 2D6.10, and 2D6.17 allelic isoformsJ Pharmacol Exp Ther200230331291130012438554
   PubMed Web of Science ®Google Scholar
• AbduljalilKFrankDGaedigkAAssessment of activity levels for CYP2D6*1, CYP2D6*2, and CYP2D6*41 genes by population pharmacokinetics of dextromethorphanClin Pharmacol Ther201088564365120881950
   PubMed Web of Science ®Google Scholar
• LovlieRDalyAKMatreGEMolvenASteenVMPolymorphisms in CYP2D6 duplication-negative individuals with the ultrarapid metabolizer phenotype: a role for the CYP2D6*35 allele in ultrarapid metabolism?Pharmacogenetics2001111455511207030
   PubMedGoogle Scholar
• ZangerUMFischerJRaimundoSComprehensive analysis of the genetic factors determining expression and function of hepatic CYP2D6Pharmacogenetics200111757358511668217
   PubMedGoogle Scholar
• HaufroidVHantsonPCYP2D6 genetic polymorphisms and their relevance for poisoning due to amfetamines, opioid analgesics and antidepressantsClin Toxicol (Phila)201553650151025998998
   PubMed Web of Science ®Google Scholar